Prof. Huihua Xiong 熊慧华
Chief Physician, Professor
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, radiotherapy, and molecular targeted therapy for breast cancer, lung cancer, cervical cancer, ovarian cancer, bone and soft tissue tumors, and gastrointestinal malignancies. Specializes in diagnosing and treating various refractory malignant tumors.
Dr. Xiong is a Chief Physician, Professor, and Head of the Comprehensive Oncology Department at Tongji Hospital. Holding a medical doctorate, Dr. Xiong has over 20 years of clinical experience since graduating in 1994. Training includes study in Japan and at MD Anderson Cancer Center in the US, funded by the Ministry of Health and China Scholarship Council. Dr. Xiong supervises master's students, leads multiple National Natural Science Foundation projects, and has published over 40 papers.
Professional roles
- Youth Committee Member, Tumor Clinical Chemotherapy Professional Committee, China Anti-Cancer Association
- Member, Hubei Anti-Cancer Association
- Member and Secretary, Oncology Professional Committee, Wuhan Medical Association
Name order: in Chinese the family name comes first (Xiong Huihua). Papers usually list the name as Huihua Xiong or Xiong H.
Selected publications
77 papers on PubMed matched by name and affiliation; 21 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Cell Mol Med, 2026 (senior author): Targeting the KIFC1-SRSF3-PKM Axis Suppresses Cervical Cancer Glycolysis and Enhances Radiosensitivity. PubMed 42764482
- Biochim Biophys Acta Rev Cancer, 2026 (senior author): Neoantigen-driven personalized vaccines for breast cancer: Platforms, nano-delivery systems, and combination strategies. PubMed 42128147
- Pharmaceutics, 2025 (senior author): The Application of Nanomaterials in Breast Cancer. PubMed 41471122
- Pharmaceutics, 2025 (senior author): Nanomedicine in the Diagnosis and Treatment of Pancreatic Cancer. PubMed 40284444
- J Gene Med, 2025 (senior author): Characterization of Immune Landscape Based on Homologous Recombination Deficiency Associated Signatures and Identification of Knockdown of ERCC6L to Promote Radiosensitivity in Breast Cancer. PubMed 39988478
- Pharmaceutics, 2024 (senior author): The Role of Pharmacogenetic-Based Pharmacokinetic Analysis in Precise Breast Cancer Treatment. PubMed 39598531
- Pharmaceuticals (Basel), 2024 (senior author): Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs. PubMed 38794221
- Int J Mol Sci, 2024 (senior author): Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives. PubMed 38791529
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion